BioTelemetry Stock News

Advisor Group Inc. reduced its position in BioTelemetry Inc (NASDAQ:BEAT) by 32.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The instituti

BioTelemetry Inc (NASDAQ:BEAT) was the target of a large increase in short interest during the month of March. As of March 13th, there was short interest totalling 2,686,100 shares, an increase of 7.0

Negative global GDP growth rate estimate is concerning, but what is even more dreadful is Nomura’s bad scenario where coronavirus “beats us.”

BioTelemetry Inc (NASDAQ:BEAT) – Dougherty & Co decreased their Q1 2020 earnings estimates for shares of BioTelemetry in a research report issued to clients and investors on Monday, March 30th. Doug

BioTelemetry (NASDAQ:BEAT) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, BidAskClub reports. A number of

Amalgamated Bank grew its position in BioTelemetry Inc (NASDAQ:BEAT) by 7.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission

To the annoyance of some shareholders, BioTelemetry (NASDAQ:BEAT) shares are down a considerable 32% in the last...

BioTelemetry Inc:

BioTelemetry, Inc. (BEAT), a leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced the activation

Only remote cardiac monitoring company whose proprietary connected system has FDA-approved indication to measure, analyze and report QT interval

The "Cardiovascular Disease Monitoring and Diagnostic Devices - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Raymond James & Associates cut its stake in BioTelemetry Inc (NASDAQ:BEAT) by 7.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). T

BioTelemetry (NASDAQ:BEAT) had its price target decreased by Benchmark from $82.00 to $55.00 in a research report released on Thursday, BenzingaRatingsTable reports. Benchmark currently has a buy rati

Analysts forecast that BioTelemetry Inc (NASDAQ:BEAT) will post $0.44 earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for BioTelemet